Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

58.83USD
20 Apr 2018
Change (% chg)

$0.19 (+0.32%)
Prev Close
$58.64
Open
$58.86
Day's High
$59.27
Day's Low
$58.67
Volume
3,825,368
Avg. Vol
3,915,961
52-wk High
$66.41
52-wk Low
$52.83

Select another date:

Tue, Apr 17 2018

BRIEF-Merck Announces First Phase 3 Studies For Pcv-15 (V114), Its Investigational Pneumococcal Disease Vaccine

* MERCK ANNOUNCES FIRST PHASE THREE STUDIES FOR PCV-15 (V114) ITS INVESTIGATIONAL PNEUMOCOCCAL DISEASE VACCINE

BRIEF-Labcyte Reaches Agreement With Merck To Supply Acoustic-Mass Spectrometry Equipment

* LABCYTE REACHES AGREEMENT WITH MERCK TO SUPPLY ACOUSTIC-MASS SPECTROMETRY EQUIPMENT

Survival data boosts Merck's Keytruda lead in lung cancer

NEW YORK/CHICAGO Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival in newly-diagnosed patients with advanced non-small cell lung cancer in a closely-watched study, cementing its lead position over Bristol-Myers Squibb Co and others in the most lucrative oncology market.

UPDATE 2-Survival data boosts Merck's Keytruda lead in lung cancer

NEW YORK/CHICAGO, April 16 Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival in newly-diagnosed patients with advanced non-small cell lung cancer in a closely-watched study, cementing its lead position over Bristol-Myers Squibb Co and others in the most lucrative oncology market.

Merck, Bristol-Myers immunotherapies impress in key lung cancer trials

April 16 Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to cement the company's lead in the most lucrative oncology market.

Judge rules antitrust claim over mumps vaccine against Merck untimely

A federal magistrate judge has ruled health care providers accusing Merck & Co Inc of monopolizing the market for the mumps vaccine cannot assert an additional attempted monopolization claim against the company.

BRIEF-Merck & Co CEO Kenneth Frazier's Total Compensation For 2017 Was $17.6 Mln Versus $21.8 Mln Last Year

* MERCK & CO INC CEO KENNETH FRAZIER'S TOTAL COMPENSATION FOR 2017 WAS $17.6 MILLION VERSUS $21.8 MILLION LAST YEAR

Merck's Keytruda helps lung cancer patients live longer in trial

Merck & Co's blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial, potentially cementing its position as the dominant player in the lucrative lung cancer market.

UPDATE 3-Merck's Keytruda helps lung cancer patients live longer in trial

* Keytruda earned $3.81 bln in revenue in 2017 (Adds analyst comments, details)

Merck's Keytruda meets main goal in lung cancer trial

April 9 Merck & Co said on Monday a late-stage trial testing its blockbuster cancer drug, Keytruda, met the main goal of helping previously untreated lung cancer patients live longer.

Select another date: